Nuvation Bio Inc. (NUVB): Total Liabilities
$289.11M
As of 2025-12-31
$490.64M
As of 2026-06-30
+156.8%
3-year compound annual growth
+112.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $289.11M | +276.3% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $76.84M | +369.6% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $16.36M | -4.1% | 2025-03-06, Balance as of period end |
| 2022-12-31 | $17.07M | -43.4% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $30.15M | +349.5% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $6.71M | n/a | 2022-02-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $289.11M | +276.3% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $123.36M | -15.4% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $52.51M | -55.1% |
| Journey Medical Corp (DERM) | 2025-12-31 | $62.74M | +4.3% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $216.01M | -12.8% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $9.90M | -84.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $564.23M | +62.8% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $20.16M | -24.3% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $177.25M | +150.5% |
Compare NUVB, FBIO, TNGX, DERM side by side · Screen every company in Pharmaceutical Preparations ↗